Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds
References (20)
- et al.
Life Sci.
(1982) - et al.
Anal. Biochem.
(1974) Anal. Bioch.
(1976)- et al.
Anal. Biochem.
(1974) - et al.
J. Pharm. Sci.
(1974) - et al.
Biochem. Pharmacol.
(1977) - et al.
Eur. J. Pharmacol.
(1983) Mol. Pharmacol.
(1982)- et al.
J. Clin. Pharmacol.
(1981) - et al.
J. Pharmacol. Exp. Ther.
(1981)
Cited by (117)
Synthetic cannabinoids (SC)
2021, Novel Psychoactive Substances: Classification, Pharmacology and ToxicologyEmerging class of omega-3 fatty acid endocannabinoids & their derivatives
2019, Prostaglandins and Other Lipid MediatorsEicosanoid mediation of cannabinoid actions
2019, Bioorganic and Medicinal ChemistrySignaling and Regulation of the Cannabinoid CB1 Receptor
2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and TreatmentCannabinoids in the Cardiovascular System
2017, Advances in PharmacologyCitation Excerpt :Following identification of THC, several other pivotal events drove the discovery in humans and animals of a ubiquitous endogenous system, coined the endocannabinoid system (ECS), that mediates the effects of Cannabis and cannabinoids. These events included evidence that THC actions are stereospecific (Mechoulam et al., 1988), a tell-tale sign of high-affinity receptor interactions, and the demonstration that cannabinoids signal in cells via a receptor-mediated decrease in adenylyl cyclase (Howlett, 1984). Synthesis of high-affinity synthetic cannabinoids contributed to the cloning of cannabinoid 1 receptor and subsequent analysis of receptor distribution and pharmacology (Gerard, Mollereau, Vassart, & Parmentier, 1991; Matsuda, Lolait, Brownstein, Young, & Bonner, 1990).